Autoimmune Lymphoproliferative Syndrome (ALPS)
A rare inherited disorder of immune regulation that causes enlarged lymph nodes and spleen, autoimmune blood cell destruction, and an increased lifetime risk of lymphoma.
- Inherited Immune Disorder
- Lymphoma Risk Monitoring
- Specialist Immunology Review
- Typical Onset
- Childhood (often before age 5)
- Inheritance Pattern
- Autosomal Dominant (FAS)
- Key Lab Marker
- Elevated Double-Negative T Cells
- Long-Term Concern
- Lymphoma Surveillance
Condition Overview
Autoimmune Lymphoproliferative Syndrome (ALPS) is a rare inherited disorder in which the body's immune cells fail to die off normally after an infection has been cleared. This defect, most often caused by mutations in the FAS gene, leads to a buildup of lymphocytes that causes chronic, non-cancerous enlargement of lymph nodes and the spleen.
Many people with ALPS also develop autoimmune disease, in which the immune system mistakenly attacks the body's own blood cells, most commonly red blood cells, platelets, and neutrophils. ALPS typically presents in early childhood, though milder forms can go unrecognized into adulthood.
Because ALPS is associated with a modestly increased lifetime risk of lymphoma, accurate diagnosis and ongoing specialist follow-up matter, both to manage day-to-day symptoms and to keep watch for the rare but important long-term complication.
Types and Subtypes
ALPS is classified by the underlying genetic defect in the cell-death (apoptosis) pathway that normally limits lymphocyte numbers.
Symptoms and Signs
The hallmark of ALPS is chronic, non-malignant enlargement of lymph nodes and the spleen, often accompanied by autoimmune attacks on blood cells.
Causes and Risk Factors
ALPS is caused by inherited or, less commonly, acquired defects in the FAS-mediated apoptosis pathway, the system that normally signals overactive immune cells to die off once an infection is resolved.
Diagnosis and Investigations
Diagnosing ALPS combines clinical history, characteristic laboratory findings, and genetic confirmation.
Disease Severity Stratification
ALPS does not use a tumor staging system; instead, clinicians stratify disease by the severity and pattern of autoimmune and lymphoproliferative activity to guide treatment intensity.
Standard Treatment Options
Treatment for ALPS is tailored to disease activity, ranging from observation in mild, stable cases to immunosuppressive therapy for active autoimmune disease, with surgery reserved for select situations.
Advanced and Emerging Treatment Options
A growing understanding of the apoptosis pathway disrupted in ALPS has led to more targeted treatment approaches beyond traditional immunosuppression.
mTOR Inhibitor Therapy
Sirolimus (Rapamycin)
Targets the mTOR pathway implicated in the abnormal lymphocyte survival seen in ALPS and has shown sustained benefit for both lymphoproliferation and autoimmune cytopenias in many patients.
Steroid-Sparing Immunomodulator
Mycophenolate Mofetil
Used as a maintenance agent to control autoimmune cytopenias while limiting long-term corticosteroid exposure.
Biologic Therapy
Rituximab (anti-CD20 antibody)
Considered in select cases of refractory autoimmune cytopenia, used with caution given infection risk in an already immune-dysregulated condition.
Cellular Therapy
Hematopoietic Stem Cell Transplant
Reserved for the most severe, refractory cases of ALPS that fail medical management; can be curative for the underlying immune defect but carries significant procedural risk.
Precision Medicine
Genetic and Pathway-Directed Counseling
Confirmed genetic diagnosis increasingly informs family screening and individualized treatment selection through specialist immunology centers.
Biomarkers & Precision Medicine
Several laboratory markers help confirm the diagnosis of ALPS, gauge disease activity, and, in some cases, anticipate treatment response.
When a Second Opinion May Be Important
Because ALPS is rare and can mimic other lymphoproliferative or autoimmune conditions, specialist input is often valuable at key decision points.
Clinical Trials and Research
Prognosis and Key Outcome Factors
Most people with ALPS live full lives with appropriate monitoring and treatment of autoimmune flares. Outcomes vary with the severity of cytopenias and lymphoproliferation, and with how consistently lymphoma surveillance is maintained.
Supportive Care and Living With ALPS
Living with ALPS involves ongoing attention to infection prevention, blood count monitoring, and emotional wellbeing alongside disease-directed treatment.
How CancerFax Helps You Explore Treatment Options
CancerFax can help you organize and have your ALPS-related medical reports reviewed by specialists, coordinate a second opinion, and connect you with centers experienced in immune dysregulation disorders.
Get a free case reviewFrequently Asked Questions
ALPS is a rare inherited disorder in which immune cells fail to die off normally, leading to chronic lymph node and spleen enlargement along with autoimmune attacks on blood cells.
Most cases are caused by mutations in the FAS gene, or less commonly FASLG or CASP10, which disrupt the normal process of programmed cell death in lymphocytes.
No. ALPS causes benign (non-cancerous) lymph node and spleen enlargement, though people with ALPS do have a modestly increased lifetime risk of developing lymphoma, which is why ongoing monitoring is recommended.
Diagnosis combines clinical findings of chronic lymphoproliferation, a characteristic elevation of double-negative T cells on flow cytometry, and often confirmatory genetic testing.
Treatment ranges from observation in mild cases to immunosuppressive medications such as corticosteroids, mycophenolate mofetil, or sirolimus for active autoimmune cytopenias.
Most forms are inherited in an autosomal dominant pattern, meaning a parent carrying the mutation has roughly a 50% chance of passing it to each child, though severity can vary widely between family members.
There is no single cure for most patients, but disease activity can often be well controlled with appropriate immunosuppressive therapy; stem cell transplant is reserved for the most severe, refractory cases.
No. Penetrance is incomplete, meaning some relatives carrying the same mutation have mild or no clinical symptoms despite testing positive genetically.
ALPS is typically managed by a clinical immunologist, often working alongside a hematologist, given the condition's combined immune and blood cell features.
Yes. CancerFax can help you organize your medical reports for specialist review, coordinate a second opinion with clinicians experienced in ALPS and related immune dysregulation disorders, and support cross-border coordination if advanced therapy or transplant evaluation is being considered.
Get Expert Guidance for ALPS
Whether you're newly diagnosed, managing autoimmune flares, or considering advanced therapy, CancerFax can help connect you with the right specialists.